摘要
目的比较甘精胰岛素(来得时)联合门冬胰岛素(诺和锐)(glargine+aspart,G+A)与胰岛素泵持续皮下输注(con-tinuous subcutaneous insulin infusion,CSII)对新患2型糖尿病胰岛细胞功能的影响。方法将新诊断的2型糖尿病患者随机分为两组:G+A组(n=20)和CSII组(n=20),分别给予甘精胰岛素联合门冬胰岛素和胰岛素泵治疗2周。治疗前后均进行口服葡萄糖耐量试验(OGTT),测定0h,0.5h,1h,2h,3h血糖和血浆胰岛素,比较治疗前后血糖水平及胰岛素、胰岛素曲线下面积(INSAUC)和胰岛素敏感指数(SIM)的变化。结果两组治疗后均较治疗前血糖显著下降(P<0.01),而各时点血浆胰岛素均明显升高(P<0.01)。治疗后两组胰岛素曲线下面积(INSAUC)胰岛素敏感指数(SIM)均明显增加(P<0.01),但是各项指标变化情况两组间比较无显著差异(P>0.05)。结论甘精胰岛素联合门冬胰岛素治疗新患2型糖尿病与胰岛素泵强化治疗血糖控制水平和改善胰岛细胞功能的作用相当。
Objective To compare the effect of insulin glargine plus insulin aspart （ glargine ＋ aspart, G ＋ A） and insulin pumps （ continuous subcutaneous insulin infusion, CSⅡ） on β-cell function of the patients newly diagnosed as type 2 diabetes mellitus. Methods Forty cases of the newly diagnosed type 2 diabetes mellitus were randomly assigned into two groups：glargine plus aspart group （G ＋ A group, n = 20 ）, insulin pump group（ CSⅡ group, n = 20）. All patients were treated for 2 weeks. Before and after treatment, the oral glucose tolerance test（OGTF） was conducted to detect the level of insulin, blood glucose, insulin area under curve （INSAUC）and insulinmediated sensitivity（SjM）. Results After treatment, the blood glucose levels significantly decreased in two groups （ P 〈 0. 01 ）. The blood insulin levels, INSAuc and SIM in two groups were significantly higher after treatment than that before treatment（ P 〈 0.01 ）. All indices showed no significant difference between two groups（P 〉 0.05 ）. Conclusion Glargine plus aspart could improve β-cell function of patients with the newly diagnosed type 2 diabetes mellitus,with the same efficacy as insulin pumps.
出处
《山西医科大学学报》
CAS
2009年第8期733-735,共3页
Journal of Shanxi Medical University
